3 results
Not approvedWill not start
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patients who have received a DCD kidney transplantation.
Approved WMOCompleted
Primary: Period II (Week 8 to Week 16)1. To demonstrate the additional antihypertensive efficacy for seated diastolic blood pressure (SeDBP) gained by adding HCTZ 12.5 or 25 mg to the treatment regimen in subjects with moderate to severe HTN not…
Approved WMOCompleted
To evaluate the safety and activity of BB3 compared to placebo in improving renal function in the immediate post-transplant period in patientswho have received a DCD kidney transplantation.